Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Barinthus Biotherapeutics (BRNS) Leases (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Leases for 6 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Leases fell 72.29% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Sep 2025, down 72.29%, and an annual FY2024 reading of $4.4 million, down 42.17% over the prior year.
  • Leases was $2.1 million for Q3 2025 at Barinthus Biotherapeutics, down from $3.3 million in the prior quarter.
  • Across five years, Leases topped out at $8.8 million in Q3 2021 and bottomed at $2.0 million in Q2 2021.
  • Average Leases over 5 years is $6.1 million, with a median of $7.4 million recorded in 2024.
  • The sharpest move saw Leases skyrocketed 308.77% in 2022, then plummeted 72.29% in 2025.
  • Year by year, Leases stood at $7.3 million in 2021, then rose by 6.83% to $7.8 million in 2022, then dropped by 2.22% to $7.6 million in 2023, then plummeted by 42.17% to $4.4 million in 2024, then tumbled by 52.94% to $2.1 million in 2025.
  • Business Quant data shows Leases for BRNS at $2.1 million in Q3 2025, $3.3 million in Q2 2025, and $3.9 million in Q1 2025.